|
|
|
|
|
» 首頁 » Microbiology » 研究筆記
|
|
|
|
Author: Amelia Virostko
1. Entamoeba histolytica
1.1. Introduction
- Causes dysentery and liver abscesses
- Cyst form enables survival in rugged external environments, trophozoite form invades and obtains nutrients once inside the host
1.2. Encounter
- Prevalent in developing countries in Africa, Asia, and South America
- Found in feces of infected humans and transmitted through the fecal-oral route via ingestion of contaminated food or water
1.3. Entry
- After entry into the GI tract, cysts undergo excystation to release trophozoites, which attach to colonic epithelial cells and cause contact-dependent lysis and phagocytosis of the cells
1.4. Spread/Multiplication
- Trophozoites multiply through binary fission
- Disseminate via portal tract to extraintestinal sites
1.5. Damage and Clinical Manifestations
- Intestinal amebiasis
- Asymptomatic infection
- Amebic colitis with inflammatory neutrophil infiltrate, followed by tissue necrosis and flask-shaped ulcers
- Presents with bloody diarrhea and abdominal pain and occasional fever
- Extraintestinal amebiasis
- Liver abscesses, or occasional pleuropulmonary, peritoneal, pericardial, or cerebral abscesses
1.6. Pathogenesis
- Galactose/N-acetylgalactosame lectin involved in adherence and contact-dependent lysis
- Amebapore important for cell lysis
- Infection induces expression of pro-inflammatory cytokines such as IL-1, IL-8, TNF-alpha, and GRO-alpha
1.7. Diagnosis and Identification
- Clinical symptoms: bloody diarrhea, abdominal pain, upper right quadrant pain, and fever
- Microscopic identification of cysts or trophozoites
- Serologic tests to detect antibodies again E. histolytica
- ELISA to detect amebic antigens in feces or PCR to detect parasite DNA
1.8. Treatment
- Cysticidal agents such as diiodohydroxyquin or diloxanide fluroate for asymptomatic cyst passers
- Metronidazole plus cysticidal agent for acute amebic colitis
1.9. Outcome
- Exposure provides some protective immunity, but not always complete
- Some patients develop chronic colitis, or life-threatening complications such as fulminant colitis or intestinal perforation
- Extraintestinal amebiasis can be fatal, particularly if pulmonary abscesses form
2. Cryptosporidium spp.
2.1. Introduction
- Mild and self-limiting watery diarrhea in immunocompetent hosts, but potential severe and chronic infection in AIDS patients
- Complicated life cycle with the following forms
- Oocysts: infectious form containing 4 motile sporozoites
- Sporozoites: invasive form released from oocysts that attach to and invade intestinal and epithelial cells and eventually develop into trophozoites
- Trophozoites: develop in a parasitophorus vaculoe within epithelial cells to form Type I meronts that divide into 8 Type I merozoites
- Merozoites: invasive form that reinvade adjacent cellsor develop into Type II meronts
- Macro and micro gamonts: sexual stages that form microgametes to form zygotes and oocysts
2.2. Encounter
- More prevalent in developing countries
- Found in feces as oocyst
- Acquire through contact with infected animals or humans, ingestion of contaminated food or water
2.3. Entry
- In the GI tract, oocyst excysts to release sporozoites, which are motile and attach to and invade small intestinal epithelial cells
2.4. Spread
- Usually localized to small intestine in immunocompetent hosts
- Infects biliary and pancreatic ducts, as well as respiratory tract in immunocompromised hosts
2.5. Multiplication
- Sporozoites dvelop into trophozoites, which form Type I meronts
- Type I meronts undergo asexual division into Type I merozoites, which develop into Type II meronts or divide into 4 Type II merozoites
- Type II merozoites develop into macro and micro gamonts
- Zygotes develop into oocysts which sporulate
2.6. Damage and Clinical Manifestations
- Villous atrophy and inflammation often develop
- Intestinal crypts may undergo hypertrophy
- Most patients develop watery diarrhea, abdominal cramps, anorexia, weight loss, and occasional fever and vomiting
2.7. Pathogenesis
- Surface adhesions and proteases
- Induces expression of pro-inflammatory cytokines that produce further inflammation
2.8. Diagnosis and Identification
- Microscopic identification
- Oocysts in fecal samples using a modified acid-fast stain or immunofluoresence assay
- ELISA to detect stool antigens
- Intestinal biopsies
2.9. Treatment
- Nitazoxanide
- Oral or parenteral rehydration, supplemental nutrition, and anti-gut motility drugs
2.10. Outcome
- No symptoms or mild self-limiting diarrhea in immunocompetent hosts
- Immunocompromised hosts may develop severe persistent and potentially fatal diarrhea and wasting
3. Giardia Lamblia
3.1. Introduction
- Pear-shaped binucleated organism with 4 pairs of flagella
- Cysts are infective form, trophozoites are vegetative active motile form
3.2. Encounter
- Found in feces in cyst form and transmitted through fecal-oral route from person-to-person contact or ingestion of contaminated food or water
- Hiker's diarrhea from ingesting water from mountain streams
3.3. Entry
- Once ingested, acid from stomach and trypsin in duodenum transform G. lamblia into vegetative trophozoite form
3.4. Spread/Multiplication
- Trophozoites divide by binary fission, attach to small intestinal epithelium, and exert pathogenic effects
- Infection localized to small intestine, and parasite does not invade or disseminate
- Trophozoites encyst on exposure to bile acid and higher pH and cysts are excreted via feces
3.5. Damage and Clinical Manifestations
- Villous atrophy and crypt hyperplasia can occur in the intestinal mucosa
- Increased inflammatory cell infiltrate and increased intraepithelial lymphocytes
- Asymptomatic to mild self-limiting diarrhea to severe chronic infection with malabsorption and weight loss
3.6. Pathogenesis
- Surface proteins and proteases
- Mucosal inflammation resulting in structural and functional abnormalities
3.7. Diagnosis and Identification
- Microscopic identification of cyst or trophozoites
- Detection of stool antigen through ELISA or immunofluoresence assay
3.8. Treatment
- Metronidazole is 1st line agent
- Furazolidone may be used in younger children
3.9. Outcome
- Usually mild and self-limiting
- Patients with humoral immunodeficiency or selective IgA deficiency may develop chronic or recurrent disease
|
|